Australia's most trusted
source of pharma news
Thursday, 30 October 2025
Posted 28 October 2025 PM
Organon boss Kevin Ali has resigned as CEO and a Member of the Board - with no severance or equity related retirement benefits - after an internal company investigation uncovered 'improper' sales practices.
Under Ali's stewardship, the company asked certain wholesalers in the US to buy more of the company's birth control implant Nexplanon than they needed over multiple quarters to enable Organon to meet guidance expectations.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.